GlassScriptPhysician profile
David S Namazy
NPI 1477558013
$28,058.81
in general payments reported to CMS, 2019-2025
8 companies · $3,890 in 2025
The $3,890 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $729 · 2021: $17K · 2022: $1,514 · 2023: $3,895 · 2024: $236 · 2025: $3,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $3,866 · Consulting Fee: $3,300 · Food and Beverage: $844 · Education: $10.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $3,865.91 |
| Consulting Fee | $3,300.00 |
| Food and Beverage | $844.07 |
| Education | $10.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20,823.51 | 2021-2023 | Ellipsys Vascular Access System |
| Bard Peripheral Vascular, INC. | $6,816.05 | 2019-2025 | Covera, Glidepath, Ultracor Breast Tissue Marker |
| Genentech, INC. | $182.85 | 2024-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $105.83 | 2024 | |
| Cardiovascular Systems INC. | $64.65 | 2019-2022 | |
| Stryker Corporation | $32.92 | 2025 | Limflow System |
| Fresenius USA Marketing, INC. | $22.35 | 2023 | Korsuva, Velphoro |
| Travere Therapeutics, INC. | $10.65 | 2023-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Namazy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.